Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

This study has been completed.
Sponsor:
Collaborator:
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer
Information provided by:
Palatin Technologies
ClinicalTrials.gov Identifier:
NCT00425256
First received: January 18, 2007
Last updated: February 22, 2011
Last verified: February 2011

January 18, 2007
February 22, 2011
February 2006
May 2007   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00425256 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
Not Provided

This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Sexual Arousal Disorder
Drug: Bremelanotide
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
May 2007
May 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Post menopausal and in general good health
  • In a stable relationship with a male partner for at least 6 months
  • Willing to attempt sexual activity once a week with your partner
Female
21 Years to 70 Years
Not Provided
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00425256
PT-141-2005-53
Not Provided
Robert Jordan, Palatin Technologies, Inc.
Palatin Technologies
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer
Not Provided
Palatin Technologies
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP